Mallion 1999.

Methods	4‐week single‐blind placebo run‐in; inclusion criteria= mean supine DBP 95‐114 mm Hg and SBP 140‐200 mm Hg after run‐in; 6‐week double‐blind treatment
Participants	Telmisartan 40 mg: n=57(38 males,19 females); mean age=58 years: baseline supine SBP=161.9(14.7) mm Hg, DBP=100.8(4.2) mm Hg, HR=70.8(10.3) bpm; Telmisartan 80 mg: n=54(35 males,19 females); mean age=57 years; baseline supine SBP=164.2(15.3) mm Hg, DBP=101.8(4.9) mm Hg, HR=69.6(8.5) bpm; Losartan 50 mg: n=57(33 males,24 females); mean age=56 years; baseline supine SBP=162.4(16.3) mm Hg, DBP=100.7(4.5) mm Hg, HR=70.6(9.1) bpm; Placebo: n=55(44 males,11 females); mean age=54 years; baseline supine SBP=156.5(14.7) mm Hg, DBP=99.2(3.9) mm Hg, HR=67.9(8.3) bpm
Interventions	Telmisartan 40 mg once daily; Telmisartan 80 mg once daily; Losartan 50 mg once daily; Placebo; taken between 7 AM and 10 AM
Outcomes	Mean change from baseline in trough supine SBP/DBP using mercury sphygmomanometer; WDAE
Notes	BP change and SE of change reported, endpoint BP and SD not reported; calculated SD from SE and N; BP data from Table 3, p. 660; Jadad score=4; funding source= not reported
Risk of bias
Bias	Authors' judgement	Support for judgement
Allocation concealment?	Unclear risk	B ‐ Unclear